


CLAIMS

What is claimed is:

1. A compound comprising a modified oligonucleotide 14 to 23 linked nucleosides in length having a nucleobase sequence comprising at least 14 contiguous nucleobases of the nucleobase sequence of SEQ ID NO: 109 or 100.
2. A compound comprising a modified oligonucleotide 22 to 30 linked nucleosides in length having a nucleobase sequence comprising the nucleobase sequence of SEQ ID NO: 109 or 100.
3. A compound comprising a first modified oligonucleotide 14 to 23 linked nucleosides in length having a nucleobase sequence comprising at least 14 contiguous nucleobases of the nucleobase sequence of SEQ ID NO: 109, and a second modified oligonucleotide 14 to 23 linked nucleosides in length having a region of complementarity to the first modified oligonucleotide.
4. The compound of claim 3, wherein the second modified oligonucleotide comprises at least 14 contiguous nucleobases of the nucleobase sequence of SEQ ID NO: 100.
5. The compound of claim 3 or 4, wherein the nucleobase sequence of the second modified oligonucleotide has at least 80% complementarity to the nucleobase sequence of SEQ ID NO: 1 or 3 over its length.
6. The compound of any one of claims 3-5, wherein the nucleobase sequence of the second modified oligonucleotide has at least 1, at least 2, or at least 3 mismatches to a region of the nucleobase sequence of SEQ ID NO: 1 or 3 that is the same length as the second modified oligonucleotide.
7. The compound of any one of claims 3-6, wherein the region of complementarity between the first modified oligonucleotide and the second modified oligonucleotide is 19 to 23 linked nucleosides in length.
8. The compound of any one of claims 3-7, wherein the first modified oligonucleotide is fully complementary to the second modified oligonucleotide.
9. The compound of any one of claims 3-8, wherein the first and/or second modified oligonucleotide comprises at least one modification selected from a modified internucleoside linkage, a modified sugar, and a modified nucleobase.
10. The compound of claim 9, wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage or a methylphosphonate internucleoside linkage.

11. The compound of claim 10, wherein the phosphorothioate internucleoside linkage or methylphosphonate internucleoside linkage is at the 3' terminus of the first or second modified oligonucleotide or at the 5' terminus of the first or second modified oligonucleotide.
12. The compound of any one of claims 9-11, wherein the modified sugar comprises a 2'-F modification or a 2'-OMe modification.
13. The compound of claim 12, wherein the second modified oligonucleotide comprises no more than ten 2'-F sugar modifications.
14. The compound of claim 12 or 13, wherein the first modified oligonucleotide comprises no more than five 2'-F sugar modifications.
15. The compound of any one claims 3-14, wherein the first modified oligonucleotide comprises a conjugate group.
16. The compound of claim 15, wherein the conjugate group is attached to the 5' end of the first modified oligonucleotide.
17. The compound of claim 15 or 16, wherein the conjugate group comprises a targeting moiety.
18. The compound of claim 17, wherein the targeting moiety comprises one or more N-Acetyl-galactosamine (GalNAc).
19. The compound of claim 18, wherein the one or more GalNAc are attached to the 2' or 3' position of the ribosyl ring of the 5' nucleoside of the first modified oligonucleotide.
20. The compound of claim 19, wherein the 5' nucleoside is of the following formula:



Formula X,

wherein:

R^9 is H, adenine, guanine, thymine, cytosine, or uracil, or adenine, guanine, thymine, cytosine, or uracil, each comprising a Protecting Group (PG), a modified nucleobase, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, or a nucleobase isostere;

L is a bond, a phosphodiester bond, a phosphorothioate bond, a triazole, a tetrazole, an amide, a reverse-amide, a carbamate, a carbonate, urea, alkyl, or heteroalkyl;

R^2 is an oligonucleotide sequence or modified oligonucleotide;

Y_1 is O, CH_2 , CH_2O , or optionally substituted NH;

Y_2 is O, CH_2 , CH_2O , or optionally substituted NH;

Y_3 is CO, SO_2 , $P(O)O$, $CH_2-O-C(O)$, $CH_2-NH-C(O)$, $CH_2-NH-SO_2$, or CH_2 ;

Y_4 is CO, SO_2 , $P(O)O$, $CH_2-O-C(O)$, $CH_2-NH-C(O)$, $CH_2-NH-SO_2$, or CH_2 ;

n_2 is 0, 1, 2, 3, 4, 5, or 6; and

each n_1 , n_3 , n_4 and n_5 is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

21. A compound comprising a first modified oligonucleotide consisting of Ref ID NO: IS1252, and a second modified oligonucleotide consisting of Ref ID NO: IA1016.
22. The compound of any one of claims 3-21, wherein the compound is a sodium salt.
23. A composition comprising the compound of any one of claims 3-22 and a pharmaceutically acceptable carrier.

24. Use of the compound of any one of claims 1-22 or the composition of claim 23 in the preparation of a medicament for the treatment of a disease, disorder, or condition associated with Complement Factor B (CFB).
25. The use of claim 24, wherein the disease, disorder, or condition is a complement pathway disease.
26. A method of inhibiting expression of CFB in an isolated cell comprising contacting the isolated cell with the compound of any one of claims 1-22 or the composition of claim 23, thereby inhibiting expression of CFB in the isolated cell.
27. The use of claim 24 or 25, wherein the disease, disorder or condition is atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3G), IgA nephropathy (IgAN), systemic lupus erythematosus (SLE), diabetic nephropathy, membranous nephropathy, polycystic kidney disease, age-related macular degeneration, thrombotic microangiopathy, myasthenia gravis, ischemia, reperfusion injury, or rheumatoid arthritis (RA).
28. The use of claim 24 or 25, wherein the disease, disorder or condition is lupus nephritis.
29. The use of any one of claims 24-27, wherein the compound or composition is to be administered parenterally to a subject.